Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
|Videos|April 26, 2022
Updates from Bausch and Lomb: US launch of FDA approved treatment for uveitis, new IOL toric calculator
Author(s)Kassi Filkins
Chuck Hess, vice president and general manager, Bausch and Lomb, discusses XIPERE™, the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, and other new things rolled out recently from the company.
Advertisement
Advertisement
Related to this article
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.
Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
3
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
4
Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery
5